سعر جافيداكلا 60 مجم 28 قرص 2022

Daclatasvir 60 mg film-coated tablets, an HCV NS5A inhibitor used in combination regimens for chronic hepatitis C.

• In combination with other medicinal products for chronic hepatitis C virus infection in adults.Population: AdultsEuropean Medicines Agency (EPAR product information)

• With daclatasvir plus sofosbuvir, the most frequently reported adverse reactions were fatigue, headache and nausea.International label, same formulation · European Medicines Agency (EPAR product information)

• Hypersensitivity to daclatasvir or any excipient.International label, same formulation · European Medicines Agency (EPAR product information)
• Co-administration with strong CYP3A4 and P-gp inducers, e.g. phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone and St John's wort.International label, same formulation · European Medicines Agency (EPAR product information)

• Must not be given as monotherapy.International label, same formulation · European Medicines Agency (EPAR product information)
• Severe bradycardia and heart block with sofosbuvir plus amiodarone (with or without other heart-rate-lowering drugs); use amiodarone only if no alternative, with close cardiac monitoring.International label, same formulation · European Medicines Agency (EPAR product information)
• Hepatitis B virus reactivation, some fatal, has been reported; screen all patients for HBV before starting.International label, same formulation · European Medicines Agency (EPAR product information)

• Strong CYP3A4/P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, St John's wort, systemic dexamethasone)Contraindicated: may lower daclatasvir exposure and cause loss of efficacy.European Medicines Agency (EPAR product information)
• Strong CYP3A4 inhibitorsReduce daclatasvir to 30 mg once daily.European Medicines Agency (EPAR product information)
• Moderate CYP3A4 inducersIncrease daclatasvir to 90 mg once daily.European Medicines Agency (EPAR product information)

• No human pregnancy data; animal studies showed embryotoxic and teratogenic effects. Should not be used during pregnancy or in women of childbearing potential not using contraception; highly effective contraception should continue for 5 weeks after completing therapy. Follow the pregnancy requirements of co-administered drugs (e.g. ribavirin).International label, same formulation · European Medicines Agency (EPAR product information)
• Not known whether excreted in human milk; animal data show excretion in milk. Mothers should not breast-feed during treatment.International label, same formulation · European Medicines Agency (EPAR product information)

• Daclatasvir: Inhibits HCV non-structural protein 5A (NS5A), an essential component of the viral replication complex, blocking viral RNA replication and virion assembly.